NCT07455071 — Peking University Third Hospital neoantigen vaccine trial
A Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247) in Study Participants With HRD-negative Epithelial Ovarian Cancer
Registry record
| Registry ID | NCT07455071 ↗ |
|---|---|
| Lead sponsor | Peking University Third Hospital |
| Collaborators | — |
| Phase | Phase NA |
| Status | Not Yet Recruiting |
| Indication | HRD-negative Epithelial Ovarian Cancer |
| Enrollment | 9 participants (target) |
| Start date | 2026-03-01 |
| Primary completion | 2027-09-30 (est.) |
| Last registry update | 16 Mar 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT07455071), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT07455071?
NCT07455071 (A Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247) in Study Participants With HRD-negative Epithelial Ovarian Cancer) is registered on ClinicalTrials.gov as Phase NA, sponsored by Peking University Third Hospital.
Is NCT07455071 recruiting?
As of the 2026-03-16 registry update, NCT07455071 is listed as "Not Yet Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT07455071?
The lead sponsor is Peking University Third Hospital.
What condition does NCT07455071 study?
The registered condition is HRD-negative Epithelial Ovarian Cancer. Primary completion is listed as 2027-09-30 (estimated).
Are results available for NCT07455071?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT07455071.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.